FDA Inspection 1220167 — Rui-Hua Xu, MD, PhD
The FDA completed an inspection of Rui-Hua Xu, MD, PhD on September 4, 2023 in Guangzhou. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- September 4, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Guangzhou (China)
Additional Details
Clinical Investigator (CI)